Adding niacin to statin therapy offers no incremental clinical benefit to patients with atherosclerotic cardiovascular disease and LDL cholesterol levels below 70 mg/dL, according to study findings published in the New England Journal of Medicine (online ahead of print).
The study included 3,414 patients who were randomly assigned to receive extended-release niacin or placebo in addition to simvastatin. The trial was stopped after a mean follow-up of three years because of a lack of efficacy. The primary endpoint—the first event of the composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, and other events—occurred in a similar proportion of niacin and placebo recipients (16.4% and 16.2%, respectively).
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.